Evaluation of the properties of WHODAS-12 measurements in individuals with Chagas disease in Brazil

Abstract

Numerous tests employed to predict cardiac and functional status are expensive and not widely accessible for a considerable number of patients, particularly those diagnosed with Chagas disease (CD) residing in remote and endemic regions. To date, there is no knowledge of studies that have validated instruments that address functionality in an expanded way, including the biopsychosocial factors in patients with CD. This study aims to evaluate the psychometric properties of the World Health Organization Disability Assessment Schedule (WHODAS 2.0), in its 12-item shortened version (WHODAS-12) when applied to patients with CD. This is a cross-sectional study of a prospective cohort that follows individuals with CD (SaMi-Trop). Data collection took place between October 2019 and March 2020. In the interviews, sociodemographic information, life habits, clinical information, and indicators of disability measured by WHODAS-12 were collected. Descriptive analysis, internal consistency and construct validity of the instrument were performed. A total of 628 patients with CD were interviewed, most were women (69.5%), their mean age was of 57 years, and most declared an average self-perception of health (43.4%). The 12 items of WHODAS-12 were distributed into three factors, which together account for 61% of the variance. The Kaiser–Meyer–Olkin (KMO) index was 0.90, indicating adequacy of the sample for factor analysis. The internal consistency of the global scale showed alpha = 0.87. The percentage of incapacity was 16.05%, indicating mild incapacity for the evaluated patients. WHODAS-12 is a valid and reliable measure to assess the disability of the Brazilian population with CD.

Validation of the 12‐item World Health Organization Disability Assessment Schedule 2.0 in individuals with schizophrenia, depression, anxiety, and diabetes in Singapore

“…Previous studies have examined the psychometric properties of the 12-item version of the WHODAS 2.0 among patients with anxiety and stress disorders [4], musculoskeletal pain conditions [8,9], neurosurgical patients [10], major depressive disorder [3], schizophrenia and psychotic disorders [5,11], trauma [6], autism spectrum [12], Huntington disease [13,14], Chagas disease [15], Parkinson disease [16], postpartum women with and without severe maternal morbidity [17] and in children, young, and older adults populations [8,[18][19][20][21][22][23]. Overall, the studies found that the instrument has high internal consistency, convergent validity, and adequate structural validity across various hypothetical models, including a 1-factor model with and without correlated residuals, a 6-factor model, and a single second-order with 6 first-order factor model.…”